Jazz Pharma presents eye-opening data at annual SLEEP meeting

Ireland-headquartered Jazz Pharmaceuticals (Nasdaq: JAZZ) has presented an update on three Phase III clinical trial programs for JZP-110, a candidate therapy for adult patients with excessive sleepiness associated with obstructive sleep apnea.

Data from the studies show statistically-significant effects at different dosing levels, corresponding to improvements in patients' ability to stay awake and their subjective levels of sleepiness.

The therapy was also well tolerated. Some of the most commonly reported adverse events were headache, nausea, decreased appetite, anxiety, and nasopharyngitis.